Now showing items 1-1 of 1

    • Long‐term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years 

      Lovell, Daniel J.; Ruperto, Nicolino; Mouy, Richard; Paz, Eliana; Rubio-Përez, Nadina; Silva, Clovis A.; Abud-Mendoza, Carlos; Burgos-Vargas, Rubén; Gerloni, Valeria; Melo-Gomes, José A.; Saad-Magalhaes, Claudia; Chavez-Corrales, J.; Huemer, Christian; Kivitz, Alan; Blanco García, Francisco J; Foeldvari, Ivan; Hofer, Michael; Huppertz, Hans-Iko; Deslandre, Chantal Job; Minden, Kirsten; Punaro, Marilynn; Block, Alan J.; Giannini, Edward H.; Martini, Alberto (Wiley, 2015-06-19)
      [Abstract] Objective. The efficacy and safety of abatacept in patients with juvenile idiopathic arthritis (JIA) who experienced an inadequate response to disease‐modifying antirheumatic drugs were previously established ...